AlphAIAlphAI — Financial news for AI agents
investing.comOCT 222 min read$ELV

Guggenheim raises Elevance stock price target on earnings growth outlook

Guggenheim raised its price target for Elevance Health (NYSE:ELV) to $485 from $460, citing strong Q3 2026 performance and 12%+ EPS growth outlook. The stock trades at $434.13 with a $94.2B market cap. Elevance reported Q3 EPS of $6.99 vs. $4.70 expected and revenue of $50.4B vs. $49.32B expected, raising its full-year outlook.

Original reporting
investing.com
Published Oct 22, 2026, 12:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 12:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ELV
Bullish
high confidence
Mentioned
$ELV
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ELVBullishMed
01

Why it matters

The earnings beat and raised outlook drive a bullish sentiment, supporting a potential price rally.

02

Market read

Fresh earnings data and analyst upgrade create a short‑term buying opportunity for ELV.

03

What to watch

Potential regulatory changes to Medicaid rates could temper future growth.

Relevance 7/10Novelty 8/10Timing: pre-market today

Background

Elevance Health reported Q3 2026 adjusted EPS of $6.99 vs $4.70 consensus and revenue of $50.4B vs $49.32B, prompting an analyst price‑target increase.

Company-level read

Ticker impact

$ELVBullishHigh confidence
Context

Guggenheim raised its price target on Elevance Health (ELV) to $485 after the company posted Q3 2026 earnings beat and raised its full-year outlook.

Expected impact

potential upside as the market prices in the higher target and earnings beat

Evidence & confidence

The price target increase reflects fresh earnings data and guidance, likely prompting buying interest.

Market effects

Sector

Strong earnings may lift broader health‑care sector expectations.

Regional

U.S. market sentiment could improve on the back of a large‑cap health insurer beat.

Global

Limited to U.S. equities; no direct global macro effect.

Counterpoint

What could challenge this read

Some investors may view the target raise as overly optimistic given reliance on non‑operating items.

Key entities

  • company
    Elevance Health Inc.

    U.S. health‑insurance provider (ticker ELV).

  • analyst
    Guggenheim

    Equity research firm that raised the price target.

Read at source← All news

Related articles

OCT 22
$ELVMed

BofA raises Elevance stock price target to $500 on earnings beat

BofA Securities raised its price target for Elevance Health (ELV) to $500 from $480, citing a 10% Q3 earnings beat and raised 2026 guidance. The company's market cap is $94.2B, P/E ratio 19.62. BofA highlights seven 2027 tailwinds, including margin improvements and share buybacks. ELV reported Q3 EPS of $6.99 vs. $4.70 estimate, revenue of $50.4B vs. $49.32B estimate.

investing.com2 min
OCT 22
$ELVMedAI 8/10

ELV Q3 deep dive: Carelon expansion and Medicaid margin actions underpin raised outlook

ELV reported Q3 revenue of $50.44B, beating estimates, with adjusted EPS of $6.99, significantly above expectations. The company raised its full-year EPS guidance to $29. Medicaid margins stabilized due to rate increases, while CarelonRx showed strong performance. Medicare Advantage saw improved margins, and AI is being used for cost management. Management expects Medicaid margin recovery in 2027. Commercial and ACA markets show disciplined pricing and product mix shifts.

finance.yahoo.com2 min
OCT 22
$ELVMed

Elevance Health Inc (ELV) (Q3 2026) Earnings Call Highlights: Raised Guidance, Strong

Elevance Health (ELV) raised guidance for 2027, citing improved health benefits margins, Carelon solutions, and operating efficiency. Q3 2026 saw a 90.6% medical loss ratio, with Medicaid, Medicare Advantage, and ACA all outperforming. Challenges include elevated Medicaid costs, commercial group cost trends, and IDR pressures. CEO Gail Boudreaux expects at least 12% adjusted EPS growth in 2027, driven by margin improvements and efficiency gains.

finance.yahoo.com3 min
OCT 22
$ELVHighAI 8/10

Elevance Health Inc (ELV) (Q3 2026) Earnings Call Highlights: Ra

Elevance Health Inc (ELV) reported Q3 2026 adjusted EPS of $6.99, exceeding expectations. The company raised its 2026 EPS guidance to at least $29 and its earnings baseline to at least $26.75. Revenue increased to $50.4 billion, driven by higher premiums and service fees. Medical membership stood at 44.9 million, with a benefit expense ratio of 90.6%. The company expects at least 12% EPS growth in 2027, driven by margin improvements and Carelon expansion.

gurufocus.com2 min